Precipio, Inc. (NASDAQ:PRPO) Short Interest Update

Precipio, Inc. (NASDAQ:PRPO) was the recipient of a significant increase in short interest during the month of May. As of May 15th, there was short interest totaling 14,627 shares, an increase of 106.7% from the April 30th total of 7,078 shares. Approximately 1.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 33,138 shares, the days-to-cover ratio is currently 0.4 days.

Precipio Stock Performance

Shares of Precipio stock opened at $22.48 on Wednesday. The company has a quick ratio of 1.33, a current ratio of 1.56 and a debt-to-equity ratio of 0.05. Precipio has a twelve month low of $9.67 and a twelve month high of $33.63. The stock has a market cap of $40.24 million, a price-to-earnings ratio of -47.83 and a beta of 1.30. The company’s fifty day moving average is $27.06 and its 200 day moving average is $25.13.

Precipio (NASDAQ:PRPO) last issued its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.81) earnings per share for the quarter. Precipio had a negative return on equity of 6.73% and a negative net margin of 3.57%.The business had revenue of $6.71 million during the quarter.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precipio in a research note on Tuesday, April 21st. Wall Street Zen cut shares of Precipio from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Trading of Precipio

Several institutional investors have recently modified their holdings of PRPO. Susquehanna International Group LLP bought a new stake in shares of Precipio in the third quarter worth $194,000. Renaissance Technologies LLC grew its stake in shares of Precipio by 10.7% in the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock worth $333,000 after purchasing an additional 1,400 shares during the last quarter. Evernest Financial Advisors LLC bought a new stake in shares of Precipio in the third quarter worth $374,000. Geode Capital Management LLC grew its stake in shares of Precipio by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 789 shares during the last quarter. Finally, Topline Capital Management LLC bought a new stake in shares of Precipio in the third quarter worth $1,158,000. Institutional investors own 10.45% of the company’s stock.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.